Results 111 to 120 of about 21,815 (182)

Precise nano-system-based drug delivery and synergistic therapy against androgen receptor-positive triple-negative breast cancer

open access: yesActa Pharmaceutica Sinica B
Targeting androgen receptor (AR) has shown great therapeutic potential in triple-negative breast cancer (TNBC), yet its efficacy remains unsatisfactory.
Fangyan Gao   +9 more
doaj   +1 more source

Comparative effectiveness and safety of enzalutamide versus abiraterone in patients with metastatic castration-resistant prostate cancer: a nationwide registry-based cohort study from Taiwan

open access: yesJournal of Cancer Research and Clinical Oncology
Purpose The real-world effectiveness and safety of abiraterone or enzalutamide in the Asian population with metastatic castration-resistant prostate cancer (mCRPC) remains unclear.
Wen-Kuan Huang   +11 more
doaj   +1 more source

Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer.

open access: yes, 2016
Treatment with androgen-targeted therapies can induce upregulation of epithelial plasticity pathways. Epithelial plasticity is known to be important for metastatic dissemination and therapeutic resistance.
Armstrong, Andrew J   +10 more
core   +1 more source

Inhibition of the Wnt/β-Catenin Pathway Overcomes Resistance to Enzalutamide in Castration-Resistant Prostate Cancer

open access: yes, 2018
Enzalutamide is a second-generation nonsteroidal antiandrogen clinically approved for the treatment of castration-resistant prostate cancer (CRPC), yet resistance to endocrine therapy has limited its success in this setting.
Pete E. Pascuzzi   +7 more
core   +1 more source

Enzalutamide inhibits PEX10 function and sensitizes prostate cancer cells to ROS activators

open access: yesCell Death and Disease
Sharply increased reactive oxygen species (ROS) are thought to induce oxidative stress, damage cell structure and cause cell death; however, its role in prostate cancer remains unclear.
Yuankang Feng   +13 more
doaj   +1 more source

Aberrant tumor metabolism to enable glucocorticoid receptor takeover in enzalutamide-resistant prostate cancer.

open access: yes, 2017
157 Background: Prostate cancer is driven by androgen stimulation of the androgen receptor (AR). The next-generation AR antagonist, enzalutamide, prolongs progression-free and overall survival, but resistance and lethal disease eventually prevail ...
Mary-Ellen Taplin   +12 more
core   +1 more source

Molecular mechanisms of enzalutamide resistance in prostate cancer

open access: yes, 2019
An estimated 30,000 men in the United States will die of metastatic prostate cancer (PCa) each year due to the development of therapy resistance, most notably resistance to second-generation antiandrogen enzalutamide.
Raj, Ganesh V., Blatt, Eliot B.
core  

Previous enzalutamide therapy and response to subsequent taxane therapy in metastatic castration-resistant prostate cancer.

open access: yes, 2015
227 Background: Cross-resistance between taxanes and androgen receptor axis targeted agents is a matter of debate in metastatic castration-resistant prostate cancer (mCRPC).
Frank Priou   +18 more
core   +1 more source

Real-world comparative effectiveness of apalutamide versus enzalutamide for prostate-specific antigen response in metastatic castration-sensitive prostate cancer

open access: yesTherapeutic Advances in Medical Oncology
Background: Deep and rapid prostate-specific antigen (PSA) response is an important indicator to consider in treatment decision-making given its predictive value for long-term clinical outcomes in metastatic castration-sensitive prostate cancer (mCSPC ...
Mehmet A. Bilen   +8 more
doaj   +1 more source

MED12 and CDK8/19 Modulate Androgen Receptor Activity and Enzalutamide Response in Prostate Cancer

open access: yes
Prostate cancer progression is driven by androgen receptor (AR) activity, which is a target for therapeutic approaches. Enzalutamide is an AR inhibitor that prolongs the survival of patients with advanced prostate cancer.
Wach, Sven   +11 more
core   +1 more source

Home - About - Disclaimer - Privacy